Barclays’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-122,925
| Closed | -$2.67M | – | 7269 |
|
|
2017
Q2 | $2.67M | Buy |
122,925
+111,008
| +932% | +$2.01M | ﹤0.01% | 1997 |
|
|
2017
Q1 | $167K | Buy |
11,917
+9,532
| +400% | +$156K | ﹤0.01% | 4488 |
|
|
2016
Q4 | $46K | Buy |
2,385
+1,457
| +157% | +$24.8K | ﹤0.01% | 5223 |
|
|
2016
Q3 | $16K | Buy |
928
+433
| +87% | +$6.42K | ﹤0.01% | 5600 |
|
|
2016
Q2 | $7K | Buy |
495
+300
| +154% | +$4.38K | ﹤0.01% | 5677 |
|
|
2016
Q1 | $3K | Sell |
195
-4,352
| -96% | -$68.2K | ﹤0.01% | 5831 |
|
|
2015
Q4 | $86K | Sell |
4,547
-6,007
| -57% | -$114K | ﹤0.01% | 4497 |
|
|
2015
Q3 | $179K | Buy |
10,554
+2,498
| +31% | +$50.9K | ﹤0.01% | 4211 |
|
|
2015
Q2 | $161K | Buy |
8,056
+1,108
| +16% | +$21.4K | ﹤0.01% | 4305 |
|
|
2015
Q1 | $118K | Sell |
6,948
-6,641
| -49% | -$113K | ﹤0.01% | 4739 |
|
|
2014
Q4 | $216K | Buy |
13,589
+1,962
| +17% | +$36K | ﹤0.01% | 4572 |
|
|
2014
Q3 | $255K | Sell |
11,627
-25,360
| -69% | -$519K | ﹤0.01% | 4524 |
|
|
2014
Q2 | $739K | Buy |
36,987
+28,652
| +344% | +$485K | ﹤0.01% | 3618 |
|
|
2014
Q1 | $151K | Buy |
8,335
+4,804
| +136% | +$66.1K | ﹤0.01% | 5063 |
|
|
2013
Q4 | $36K | Sell |
3,531
-1,206
| -25% | -$14.6K | ﹤0.01% | 6409 |
|
|
2013
Q3 | $57K | Buy |
4,737
+4,123
| +671% | +$50.7K | ﹤0.01% | 5987 |
|
|
2013
Q2 | $7K | Buy |
+614
| New | +$6.65K | ﹤0.01% | 7276 |
|
Other funds holding AMRI
Barclays's AMRI Position: Q3 2017 in Review
Barclays sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 122,925 shares — an estimated $2.67M sold.
Barclays first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $2.67M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Barclays reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Barclays sold 122,925 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.67M.
- Barclays first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Barclays's Albany Molecular Research Inc position peaked at $2.67M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Barclays's 13F filing for Q3 2017, filed 14 Nov 2017.